Phase 2 Trial of SL-701, a Novel Immunotherapy Targeting IL-13R⍺2, EphA2, and Survivin, in Adults with Recurrent Glioblastoma (GBM)
Phase 2 Trial of SL-701, a Novel Immunotherapy Targeting IL-13R⍺2, EphA2, and…
Phase 2 Trial of SL-701, a Novel Immunotherapy Targeting IL-13R⍺2, EphA2, and Survivin, in Adults with Recurrent Glioblastoma (GBM).
Phase 2 Trial of SL-701, a Novel Immunotherapy Targeting IL-13R⍺2, EphA2, and…
Results of Pivotal Phase 2 Trial of Tagraxofusp (SL-401) in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).
Results of Pivotal Phase 2 Trial of Tagraxofusp (SL-401) in Patients with…
Results from Ongoing Phase 1/2 Trial of SL-401 in Patients with Relapsed/Refractory CMML. ASH 2018.
Results from Ongoing Phase 1/2 Trial of SL-401 in Patients with…
Results from Ongoing Phase 1/2 Trial of SL-401 in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis.
Results from Ongoing Phase 1/2 Trial of SL-401 in Patients with Intermediate or…
Phase 2 trial of SL-701 in Relapsed/Refractory (r/r) Glioblastoma (GBM) Indicates Preliminary Correlation of Immune Response with Longer-term Survival
Phase 2 trial of SL-701 in Relapsed/Refractory (r/r) Glioblastoma (GBM)…
Results of Pivotal Phase 2 Trial of SL-401 in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm
Results of Pivotal Phase 2 Trial of SL-401 in Patients with Blastic…
Results from Ongoing Phase 1/2 Trial of SL-401 in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis
Results from Ongoing Phase 1/2 Trial of SL-401 in Patients with Intermediate or…
Results from Ongoing Phase ½ Trial of SL-401 in Patients with Relapsed/Refractory CMML. EHA 2018.
Results from Ongoing Phase 1/2 Trial of SL-401 in Patients with…
SL-401, a Novel Targeted Therapy Directed to the Interleukin-3 Receptor (CD123), Kills Plasmacytoid Dendritic Cells (pDCs) from Systemic Sclerosis Patients
SL-401, a Novel Targeted Therapy Directed to the Interleukin-3 Receptor…